TRANSCRANIAL
MRgFUS BRAIN TREATMENT
Transcranial MRI-guided focused ultrasound steers thousands of precisely timed ultrasound beams through the intact skull to ablate targets deep in the brain — without craniotomy, stereotactic frame, or radiation — delivering immediate, durable results for tremor disorders and early evidence in brain tumours.
analyticsAt a Glance
- check_circleFDA-approved for essential tremor (2016) and Parkinson's disease tremor (2018) — most treated patients achieve immediate tremor elimination
- check_circleUnder investigation for glioblastoma (blood-brain barrier opening for drug delivery), brain metastases, and neuropathic pain
- check_circleNo craniotomy — focused ultrasound passes through intact skull using phased-array beam steering and MR thermometry guidance
- check_circleAvailable at specialist neuroscience centres in China and accessible to international patients via CancerFax
How Transcranial MRgFUS Works: Treating Through the Intact Skull
The skull poses an enormous acoustic challenge for brain-directed focused ultrasound. Bone both absorbs ultrasound energy (heating the skull itself) and refracts the beam, distorting the focal geometry. Transcranial MRgFUS overcomes both problems through two innovations: a 1,024-element phased array transducer that models and compensates for each skull's unique acoustic profile using pre-treatment CT data, and continuous MR thermometry that maps temperature in brain tissue and the skull surface in real time.
“The skull was once considered an impenetrable barrier to focused ultrasound — today, a 1,024-element array steers through it with sub-millimetre accuracy while MRI watches every degree of temperature change in real time.”
Skull Compensation via CT-Based Modelling
Pre-treatment CT defines the acoustic density, thickness, and geometry of every cubic millimetre of the patient's skull. This data is loaded into the treatment planning system, which calculates individual phase delays for each of the 1,024 transducer elements — compensating for the skull's refractive distortion and ensuring all beams converge precisely at the intracranial target despite passing through irregular bone.
MR Thermometry: Real-Time Brain Temperature Mapping
During sonication, proton resonance frequency (PRF) MR thermometry maps temperature changes throughout the treatment volume and skull with 1°C accuracy updated every 3–4 seconds. This allows the operator to confirm focal heating at the target, protect the skull surface from overheating, and immediately stop treatment if an unexpected thermal gradient develops in a critical structure.
Key Clinical Numbers
FDA registration trial data and subsequent real-world studies establish the following benchmarks for the two approved neurological indications.
- ~75%Tremor reduction at 12 months (essential tremor)Reported in the FDA registration RCT (Elias et al., NEJM 2016) — immediate, durable reduction in hand tremor after a single thalamotomy session.
- 62%Tremor rating improvement (Parkinson's disease)Phase III trial (Bond et al., NEJM 2017) — unilateral VIM thalamotomy for Parkinson's tremor unresponsive to medication.
- 0Craniotomies required for any tcMRgFUS procedureThe entire brain treatment is delivered through the intact skull — no skull drilling, no surgical opening, no intracranial instrumentation.
- 1Number of sessions to treat essential tremorSingle treatment session — immediate tremor suppression during the procedure, with durable effect maintained at 1 and 2 years in published follow-up.
Transcranial MRgFUS: Approved and Investigational Indications
The clinical application of tcMRgFUS spans from approved neurological disorders to active oncological investigation — with a clear regulatory and evidence hierarchy.
| Indication | Regulatory Status | Mechanism | Evidence Summary |
|---|---|---|---|
| Essential tremor (dominant hand) | FDA approved (2016), CE marked | Ventral intermediate nucleus (VIM) thalamotomy — thermal ablation | Phase III RCT: ~75% tremor reduction; durable at 2 years; single session |
| Parkinson's disease tremor | FDA approved (2018), CE marked | VIM thalamotomy — same target as essential tremor | Phase III RCT: 62% improvement; tremor-dominant PD; unilateral treatment |
| Obsessive-compulsive disorder (OCD) | FDA Breakthrough Designation | Anterior limb of internal capsule capsulotomy | Pilot data promising; pivotal trial ongoing |
| Major depressive disorder | Clinical trials | Subcallosal cingulate / other limbic targets | Early phase; centres selected; data emerging |
| Neuropathic pain | Clinical trials / CE-marked use | Central lateral thalamotomy | CE-marked in some jurisdictions; prospective series data |
| Glioblastoma — BBB opening for drug delivery | Phase I/II trials | Low-intensity pulsed HIFU opens blood-brain barrier transiently | Allows CNS chemotherapy delivery; safety established; efficacy trials ongoing |
| Brain metastases — focal ablation | Early clinical investigation | Thermal ablation of MRI-visible brain mets ≤2 cm | Pilot cases reported; no randomised data yet; feasibility confirmed |
| Chronic nociceptive pain (thalamic) | Limited use / research | Thermal lesioning of pain relay thalamic nuclei | Historical surgical precedent; MRgFUS data limited to small series |
The Transcranial MRgFUS Procedure: Step by Step
The treatment is performed awake inside the MRI scanner — no sedation or general anaesthesia, because real-time neurological feedback from the patient is part of the procedure's safety monitoring.
- 1
Head Shaving and Frame Placement
The patient's head is fully shaved to eliminate hair-related acoustic interference. A stereotactic frame (MR-compatible) is fixed to the skull with four pins under local anaesthesia. This frame interfaces with the hemispherical transducer helmet that encases the head during treatment.
- 2
CT Skull Mapping
A head CT (or use of pre-treatment planning CT) provides the skull bone density ratio and geometry data loaded into the planning software — essential for calculating the element-by-element phase delays that steer all 1,024 beams through the skull to the same focal point.
- 3
Entry Into MRI Scanner
The patient and transducer helmet assembly slide into the MRI bore. The transducer is coupled to the patient's shaved skull with chilled water (maintained at ~15°C) circulating within the helmet — cooling the skull surface to prevent overheating during sonication.
- 4
Low-Energy Test Sonications
Progressively increasing-energy test sonications are delivered while the patient performs tremor assessment tasks in real time. This calibration phase confirms focal targeting accuracy and the patient's individual skull transmission coefficient before therapeutic energy is applied.
- 5
Therapeutic Sonications
Full therapeutic energy is delivered in 10–20 second sonications, raising the target to 54–60°C for thalamotomy. MR thermometry confirms focal temperature. The patient is assessed for tremor reduction and neurological side effects between each sonication — immediate feedback guides the operator.
- 6
Frame Removal and Discharge
The stereotactic frame is removed. Most patients walk out of the treatment suite with immediate tremor suppression. Overnight observation is standard. A light headache and mild dizziness are common for 24–48 hours.
Transcranial MRgFUS vs DBS for Essential Tremor
Deep brain stimulation (DBS) is the established surgical standard for medication-refractory essential tremor. tcMRgFUS offers a non-surgical alternative with important differences in risk profile and reversibility.
tcMRgFUS
- No craniotomy — no intracranial hardwareNo skull drilling, no electrode implantation, no subcutaneous battery pack. Eliminates hardware infection, lead migration, and device failure risks.
- No anaesthesia requiredPerformed awake in the MRI scanner — suitable for elderly or medically frail patients who are not safe candidates for general anaesthesia.
- Immediate effect — single sessionTremor reduction is observed during the procedure itself; no programming period, no adjustment visits, no battery replacement surgery.
- No ongoing hardware managementAfter tcMRgFUS, no device is present — no follow-up appointments for battery checks, programming adjustments, or implant complications.
Deep Brain Stimulation (DBS)
- DBS is adjustable and reversibleThe DBS stimulation parameters can be adjusted as the disease progresses, turned off if side effects occur, or upgraded to a newer device — tcMRgFUS creates a permanent lesion that cannot be adjusted.
- DBS can be bilateralBoth sides of the brain can be treated with bilateral DBS. tcMRgFUS bilateral thalamotomy carries a significantly higher risk of speech and balance side effects — currently, most centres perform only unilateral tcMRgFUS.
- DBS has longer follow-up dataDBS has decades of published long-term outcome data. tcMRgFUS 5-year data are emerging but substantially less mature.
- DBS suitable for thicker or older skullsPatients with skull density ratios <0.4 (older or very dense skulls) may not achieve adequate transcranial HIFU penetration — DBS has no such constraint.
More from the HIFU Therapy Resource Library
Continue exploring HIFU — from the technology platforms to other cancer and non-cancer applications.
- HIFU Therapy — Complete Treatment Guide
- HIFU Physics: How Acoustic Focusing Destroys Tissue
- HIFU Technology Platforms: HAIFU, JC, and MRI-Guided Systems
- What Is HIFU? Non-Invasive Focused Ultrasound Explained
- HIFU for Bone Metastases: Non-Invasive Pain Palliation
- HIFU for Prostate Cancer: Whole-Gland and Focal Treatment
Frequently Asked Questions
Common questions from patients considering transcranial MRgFUS for neurological conditions or brain tumours.
About Transcranial MRgFUS
Why is transcranial MRgFUS only done on one side of the brain?
Bilateral thalamotomy — ablating both thalami — carries a high risk of dysarthria (slurred speech), ataxia (balance impairment), and cognitive effects. The left and right thalami are connected to overlapping speech and coordination networks, and bilateral permanent lesions produce additive and sometimes severe functional deficits. For this reason, regulatory approvals for essential tremor and Parkinson's tremor are for unilateral treatment of the dominant hand side only. Research into staged bilateral approaches with careful patient selection is ongoing but not yet standard practice.
My glioblastoma doctor mentioned blood-brain barrier opening with HIFU — what does this mean?
Low-intensity pulsed HIFU — combined with intravenously administered microbubbles — temporarily and reversibly opens the blood-brain barrier (BBB) in targeted brain regions. The BBB normally prevents most chemotherapy drugs from reaching brain tumours. HIFU-induced BBB opening creates a 6–24 hour window during which drugs like temozolomide, carboplatin, or immunotherapy agents can penetrate the tumour at concentrations otherwise unachievable. This approach is in Phase I/II clinical trials for glioblastoma and is showing promising safety and drug delivery signals. It is not yet a standard treatment but is available at selected trial centres.
How do I know if my skull is thick enough for transcranial MRgFUS?
This is determined by the skull density ratio (SDR) — the ratio of trabecular to cortical bone density measured on CT. An SDR above 0.4 is generally required for adequate ultrasound transmission through the skull. Patients with SDR below 0.4 (older patients with dense, highly mineralised skulls) cannot be treated with the current generation of transcranial HIFU systems. Your pre-procedure CT will be used to calculate your SDR — this is one of the first eligibility checks performed at the tcMRgFUS assessment visit.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Explore Transcranial MRgFUS for Your Neurological Condition
CancerFax connects patients with neurological disorders or brain tumours to specialist transcranial MRgFUS centres in China — where the technology is in clinical use for FDA-approved neurological indications and selected oncological applications.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified neurologist or neurosurgeon before making treatment decisions.